FIRST AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 10th, 2011 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations
WHEREAS, Progenics Pharmaceuticals, Inc. (the “Corporation”) and Paul J. Maddon (“Maddon”) are each a party (the “Parties”) to an employment agreement (the “2007 Agreement”), dated as of December 31, 2007; and
LICENSE AGREEMENT by and between SALIX PHARMACEUTICALS, INC. and PROGENICS PHARMACEUTICALS, INC. PROGENICS PHARMACEUTICALS NEVADA, INC. and EXCELSIOR LIFE SCIENCES IRELAND LIMITED Dated as of 3 February 2011License Agreement • May 10th, 2011 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (this “Agreement”) is made and entered into as of 3 February 2011 (the “Effective Date”), by and between Salix Pharmaceuticals, Inc., a corporation existing under the laws of California and having a place of business at 1700 Perimeter Park Drive, Morrisville, NC 27560 (“Salix”), and Progenics Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, NY 10591 (“Progenics”), Progenics Pharmaceuticals Nevada, Inc., a corporation organized and existing under the laws of the State of Nevada and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA and a wholly-owned subsidiary of Progenics (“ProNev”), and Excelsior Life Sciences Ireland Limited, a corporation organized and existing under the laws of Ireland and having a principal place of business at 25/28 North Wall Quay, Dublin 1 Ireland and a wholly-ow
ContractLicense Agreement • May 10th, 2011 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AGREEMENT (the “Agreement”) is entered into as of February 3, 2011, and is effective as of the Effective Date (as herein after defined), by and among the University of Chicago, acting on behalf of itself and its affiliate ARCH Development Corporation (the “University”), Progenics Pharmaceuticals, Inc. (“Progenics”), Progenics Pharmaceuticals Nevada, Inc., a wholly-owned subsidiary of Progenics (“ProNev;” and, together with Progenics, the “Progenics Parties”), and Salix Pharmaceuticals, Inc. (“Salix”).
